According to The Legal Intelligencer, approximately 5,800 Risperdal lawsuits have been filed and that number may triple by the end of the year. These new cases filed since January 1, 2017 represent a 185 percent increase in Risperdal complaints. Judge Arnold New, supervising judge of the Philadelphia Complex Litigation Center, confirmed that the Risperdal mass-tort is the largest in the system. (These cases are in addition to about 17,000 Risperdal lawsuits filed nationwide in federal and state courts.)
Unless Risperdal attorneys negotiate a settlement or another resolution, about ten Risperdal trials are slated for the Philadelphia Courts at the end of 2017 and into the first half of 2018.
Every one of the 5,800 complaints accuse Johnson & Johnson of aggressively marketing Risperdal for unapproved uses in children and downplaying gynecomastia, a side effect in which young boys develop female breast tissue.
Johnson & Johnson was fined $2.2 billion in 2013 to end civil and criminal investigations into kickbacks to pharmacists and the marketing of the pharmaceuticals Risperdal and Invega and the heart drug Natrecor for off-label uses. Reuters reported that, from 1999 through 2005, J&J and its subsidiary Janssen Pharmaceuticals Inc. promoted Risperdal for unapproved uses, including controlling aggression and anxiety in elderly dementia patients and treating behavioral disturbances in children and in individuals with disabilities.
READ MORE RISPERDAL LEGAL NEWS
And why is Risperdal prescribed to millions of patients? One reason is that it’s prescribed off-label. Research and lawsuit settlements indicate that it is frequently prescribed off-label for uses not approved by the FDA such as the treatment of ADHD. Since its FDA approval in 1993, Johnson & Johnson and Janssen Pharmaceuticals have made billions of dollars in Risperdal sales.